Curated News
By: NewsRamp Editorial Staff
July 06, 2026

VERAXA Biotech Advances BiTAC Platform, Targets 2028 IND

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • VERAXA Biotech's BiTAC platform advances four T-cell engager programs targeting solid tumors, offering a competitive edge in cancer therapy.
  • VERAXA prioritizes BiTAC portfolio investment and plans to monetize non-BiTAC assets to finance VXA-102 IND/CTA readiness by early 2028.
  • VERAXA's next-generation cancer therapies aim to improve outcomes for solid tumor patients, making tomorrow better through innovative treatments.
  • VERAXA's BiTAC platform, born from EMBL breakthroughs, uses bispecific T-cell engagers to precisely target and destroy cancer cells.

Impact - Why it Matters

This news matters because VERAXA's BiTAC platform represents a novel approach to cancer immunotherapy, specifically targeting solid tumors with T-cell engagers and ADCs. The company's progress and potential partnerships could accelerate the development of more effective treatments for hard-to-treat cancers, offering new hope for patients. For investors, VERAXA's strategic focus on monetizing non-core assets to fund its lead candidate VXA-102 indicates a disciplined approach to capital management, potentially reducing dilution risk. The strong industry interest validates the technology, and successful IND filing by 2028 could be a significant milestone, making this a stock to watch in the biotech sector.

Summary

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (“ADC”) programs and two non-BiTAC assets available for partnering. VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.

Company executives also cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies. The full press release can be accessed at https://ibn.fm/xTF5q.

VERAXA Biotech AG, founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), is building a premier engine for next-generation antibody-based therapeutics. The company's BiTAC(R) platform is a registered trademark, and its pipeline includes innovative bispecific T cell engagers and ADCs. For investors, the latest news on VRXA is available at http://ibn.fm/VRXA. BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, covers developments in biotech and life sciences, offering services like press release distribution and social media amplification through its network.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Biotech Advances BiTAC Platform, Targets 2028 IND

blockchain registration record for this content.